课题基金 / 基金详情

TOPICAL B-BLOCKER SIDE EFFECTS IN ELDERLY

TOPICAL B-BLOCKER SIDE EFFECTS IN ELDERLY
局部 B 受体阻滞剂对老年人的副作用
批准号:
3264735
负责人:
JEROME L AVORN
金额:
$16.04万
依托单位国家:
美国
项目类别:
财政年份:
1989
资助国家:
美国
项目状态:
已结题
起止时间:
1989-07-01 至 1991-06-30

项目摘要

项目成果

JEROME L AVORN的其他基金

相关文献

中文摘要
翻译
局部应用受体阻滞剂是青光眼的主要治疗方法
英文摘要
Topically applied beta-blockers are a mainstay of glaucoma treatment. While there exist good data concerning the efficacy of topical beta-blockers in reducing intraocular pressure, very little is known about the epidemiology of systemic adverse effects from this common therapy, particularly in the elderly. This study will analyze the pharmaco-epidemiology of ophthalmic beta-blocker side effects in a population of over 1 million patients in New Jersey, through computer-assisted investigation of a dataset of all recipients in the New Jersey Medicaid program (N=975,700), as well as int the Pharmacy Assistance for the Aged and Disabled program (PAAD) (N=250,000). These complete records of medication use data and all other reimbursed health care services (including office visits, emergency services, hospitalizations, and long-term care) will be tracked on a patient- specific basis and supplemented with all Medicare claims data (Parts A and B, also on a person-specific basis). Epidemiologic analysis will take the form of follow-up (cohort) studies, after exposure to an ophthalmic beta-blocker, either timolol or betaxolol. Outcomes of interest will be the rate of health care encounters for clinical events such as congestive heart failure, bronchospasm, depression, or confusion. These will be tracked not only by measures such as physician visits or hospital stays, but also by tracing the pattern of use of medications prescribed to treat these conditions (e.g. diuretics, digoxin, bronchodilators, antidepressants, etc.). Standard epidemiologic techniques will be used to answer the following questions: (1) Is there an increased risk of the systemic side effects studied in glaucoma patients using topical beta-blockers, and what is the magnitude of such risk? (2) Are there important co-factors that predict elevated risk among certain subgroups of glaucoma patients, such as age, specific comorbidity, co-existing medication use, etc.? (3) Is there a clinically important difference between betaxolol and timolol in regard to the outcomes studied? (4) If differences in adverse effect risk are found in patients using these medications, what are its implications for practice in the care of glaucoma patients?
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DRUGS AND AGING--DEMOGRAPHIC, CLINICAL, AND COST DATA
  • 批准号:
    6190122
  • 项目类别:
  • 资助金额:
    $8.48万
  • 财政年份:
    2000
  • 负责人:
    JEROME L AVORN
  • 依托单位:
RISKY GERIATRIC BENZODIAZEPINE USE--PREDICTORS & TRENDS
  • 批准号:
    2488631
  • 项目类别:
  • 资助金额:
    $4.14万
  • 财政年份:
    1996
  • 负责人:
    JEROME L AVORN
  • 依托单位:
RISKY GERIATRIC BENZODIAZEPINE USE--PREDICTORS & TRENDS
  • 批准号:
    2517966
  • 项目类别:
  • 资助金额:
    $26.94万
  • 财政年份:
    1996
  • 负责人:
    JEROME L AVORN
  • 依托单位:
RISKY GERIATRIC BENZODIAZEPINE USE--PREDICTORS & TRENDS
  • 批准号:
    2013418
  • 项目类别:
  • 资助金额:
    $24.16万
  • 财政年份:
    1996
  • 负责人:
    JEROME L AVORN
  • 依托单位: